Win More Pharma Studies with Objective Behavioral Endpoints
Add AI-validated behavioral endpoints to your proposals without increasing headcount, timelines, or operational complexity. Deliver faster, more consistent, audit-ready results under your brand.
Measurable Impact on Study Economics
CROs Are Under Pressure to Do More with Less
Pharma sponsors are demanding more endpoints, stronger regulatory evidence, and faster timelines — without expanding budgets or tolerating inconsistency.
More Endpoints, Same Timelines
Sponsors expect deeper behavioral data without extending study duration
Consistency Across Sites
Manual scoring introduces variability that weakens statistical power
Regulatory Documentation
Submission standards require reproducible, audit-ready evidence
Capacity Constraints
Scaling studies typically requires proportional increases in staff
Expand Your Capability Without Expanding Cost
OneKind operates as an invisible behavioral analysis layer within your existing workflow.
No protocol redesign
No new infrastructure
No retraining required
Audit trail included — every analysis ships with run ID, model version, dataset hash, and timestamps. No additional setup required.
Delivered under your brand. You maintain full client ownership.
A New, Differentiated Service Line
Win More Studies
Offer objective, AI-validated endpoints in competitive bids
Increase Revenue per Study
Add high-value behavioral endpoints without adding cost base
Improve Delivery Confidence
Eliminate inter-rater variability and reduce risk of inconclusive trials. Audit-ready delivery packages from day one.
Scale Without Hiring
Process more studies concurrently without expanding teams
Operationally Ready at Scale
Statistics calculated from client-evaluated credibility tests and operational deployments. Specific study details withheld for client confidentiality.
Add Behavioral Endpoints to Your Next Proposal
Deploy objective, regulator-ready behavioral analysis without changing how your studies run.